Inventor · disambiguated record

Mark K. Schlegel

Also filed as: SCHLEGEL MARK · SCHLEGEL MARK K

30 granted patents·40 pending applications·68 citations·filing 2017–2025

95Inventor score

Technology areasC12N A61K A61P C07H C12Y

Files withALNYLAM PHARMACEUTICALS INC70

Top patents by PatentIndex Score

70 records

0197US11015201B2Angiotensinogen (AGT) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2020·Granted May 25, 2021·6 cites·15 claims
0296US11504391B1Modified RNA agents with reduced off-target effectALNYLAM PHARMACEUTICALS INC·Filed 2017·Granted Nov 22, 2022·18 cites·42 claims
0395US11834661B2Angiotensinogen (AGT) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2021·Granted Dec 5, 2023·2 cites·65 claims
0494US11326166B1Xanthine dehydrogenase (XDH) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2021·Granted May 10, 2022·3 cites·29 claims
0594US11149276B2Patatin-like phospholipase domain containing 3 (PNPLA3) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2021·Granted Oct 19, 2021·4 cites·30 claims
0694US10995336B2Serpina1 iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2019·Granted May 4, 2021·8 cites·41 claims
0793US11926832B2Ketohexokinase (KHK) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2022·Granted Mar 12, 2024·4 cites·30 claims
0893US11208660B1Coronavirus iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2021·Granted Dec 28, 2021·3 cites·30 claims
0992US11959081B2Transthyretin (TTR) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2022·Granted Apr 16, 2024·1 cites·30 claims
1091US11965166B2Complement factor B (CFB) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2023·Granted Apr 23, 2024·1 cites·30 claims
1191US11492623B2Hepatitis B virus (HBV) dsRNA agent compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2019·Granted Nov 8, 2022·4 cites·36 claims
1290US11993774B2Huntingtin (HTT) iRNA agent compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2023·Granted May 28, 2024·1 cites·30 claims
1388US12049630B2Factor XII (F12) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2023·Granted Jul 30, 2024·1 cites·30 claims
1488US11725207B2Serpina1 iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2021·Granted Aug 15, 2023·1 cites·123 claims
1587US11613751B2Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2022·Granted Mar 28, 2023·6 cites·30 claims
1685US11597932B2Chirally-enriched double-stranded RNA agentsALNYLAM PHARMACEUTICALS INC·Filed 2018·Granted Mar 7, 2023·3 cites·24 claims
1785US2025207131A1Modified rna agents with reduced off-target effectALNYLAM PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
1884US11162103B2Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2021·Granted Nov 2, 2021·1 cites·23 claims
1983US11866710B2Transmembrane protease, serine 6 (TMPRSS6) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2023·Granted Jan 9, 2024·1 cites·46 claims
2083US2025043279A1SERPINA1 iRNA COMPOSITIONS AND METHODS OF USE THEREOFALNYLAM PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
2182US12331297B2Coagulation factor V (F5) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2024·Granted Jun 17, 2025·0 cites·28 claims
2282US12258565B2Complement component C3 iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2024·Granted Mar 25, 2025·0 cites·28 claims
2381US12404508B2Ketohexokinase (KHK) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2023·Granted Sep 2, 2025·0 cites·29 claims
2479US12473550B2Coagulation factor V (F5) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2023·Granted Nov 18, 2025·0 cites·55 claims
2579US12275938B2Modified RNA agents with reduced off-target effectALNYLAM PHARMACEUTICALS INC·Filed 2022·Granted Apr 15, 2025·0 cites·38 claims
2677US2024409929A1Transthyretin (ttr) irna compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
2776US2023256001A1Modified rna agents with reduced off-target effectALNYLAM PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
2875US12416006B2Cell death-inducing DFFA-like effector B (CIDEB) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2024·Granted Sep 16, 2025·0 cites·23 claims
2975US2025115911A1Snca-targeting sirna compositions for treating snca-associated diseaseALNYLAM PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
3075US2025027080A1Complement factor b (cfb) irna compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
3175US2024368594A1Huntingtin (htt) irna agent compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
3274US12365896B2Complement component C3 iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2022·Granted Jul 22, 2025·0 cites·52 claims
3374US2025059541A1Snca-targeting sirna compositions for treating snca-associated diseaseALNYLAM PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
3473US11649459B2Superoxide dismutase 1 (SOD1) iRNA compositions and methods of use thereof for treating or preventing superoxide dismutase 1-(SOD1-) associated neurodegenerative diseasesALNYLAM PHARMACEUTICALS INC·Filed 2022·Granted May 16, 2023·0 cites·30 claims
3573US2025084418A1Compositions and methods for silencing carbonic anhydrase 2 expressionALNYLAM PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
3672US12247203B2Modified RNA agents with reduced off-target effectALNYLAM PHARMACEUTICALS INC·Filed 2019·Granted Mar 11, 2025·0 cites·20 claims
3772US2024150767A1SUPEROXIDE DISMUTASE 1 (SOD1) iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING OR PREVENTING SUPEROXIDE DISMUTASE 1- (SOD1-) ASSOCIATED NEURODEGENERATIVE DISEASESALNYLAM PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
3872US2024401056A1FACTOR XII (F12) iRNA COMPOSITIONS AND METHODS OF USE THEREOFALNYLAM PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
3970US12391945B2Coronavirus IRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2021·Granted Aug 19, 2025·0 cites·22 claims
4070US12173289B2Hepatitis B virus (HBV) dsRNA agent compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2022·Granted Dec 24, 2024·0 cites·32 claims
4170US2023122244A1Chirally-enriched double-stranded rna agentsALNYLAM PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
4270US2025011776A1Huntingtin (htt) irna agent compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
4369US2024318184A1PATATIN-LIKE PHOSPHOLIPASE DOMAIN CONTAINING 3 (PNPLA3) iRNA COMPOSITIONS AND METHODS OF USE THEREOFALNYLAM PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
4469US2025205272A1Modified rna agents with reduced off-target effectALNYLAM PHARMACEUTICALS INC·Filed 2025·Application pending·0 cites
4567US2024182905A1TRANSMEMBRANE PROTEASE, SERINE 6 (TMPRSS6) iRNA COMPOSITIONS AND METHODS OF USE THEREOFALNYLAM PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
4667US2022411801A1XANTHINE DEHYDROGENASE (XDH) iRNA COMPOSITIONS AND METHODS OF USE THEREOFALNYLAM PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
4766US12480125B2Patatin-like phospholipase domain containing 3 (PNPLA3) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2021·Granted Nov 25, 2025·0 cites·20 claims
4866US2024124882A1Prion protein (prnp) irna compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
4966US2024392294A1Irna compositions and methods for silencing angiotensinogen (agt)ALNYLAM PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
5065US2024254493A1Compositions and methods for silencing carbonic anhydrase 2 expressionALNYLAM PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites

Showing the top 50 of 70 patent records by PatentIndex Score.

Join the waitlist — get patent alerts

Get an alert when Mark K. Schlegel files or is granted a new patent.

We store only your email — no account needed. See our privacy policy.

Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →